Results 171 to 180 of about 9,712 (187)
Some of the next articles are maybe not open access.
Basic Techniques for Studies of iNKT Cells and MAIT Cells
2014Invariant natural killer T (iNKT) cells and mucosal-associated invariant T cells (MAIT cells) are T cell subsets belonging to innate-like lymphocytes. These innate-like lymphocytes express semi-invariant T cell receptors, but exert diverse functions and thus are involved in various types of immune responses. As iNKT cells and MAIT cells are abundant in
Asako, Chiba, Sachiko, Miyake
openaire +2 more sources
2008
The complexity of the immune system requires mechanisms, cellular and molecular, that coordinate early innate immune responses to those of late adaptive immune responses. One type of immune cell that is able to mediate this bridge between innate immunity and adaptive immunity is the invariant natural killer T (iNKT) cell. In recent years, much research
Dalam Ly, Terry L. Delovitch
openaire +1 more source
The complexity of the immune system requires mechanisms, cellular and molecular, that coordinate early innate immune responses to those of late adaptive immune responses. One type of immune cell that is able to mediate this bridge between innate immunity and adaptive immunity is the invariant natural killer T (iNKT) cell. In recent years, much research
Dalam Ly, Terry L. Delovitch
openaire +1 more source
iNKT cells need UTX-tra demethylation
Nature Immunology, 2017The epigenetic regulation of gene expression by the histone demethylase UTX is central to the development of invariant natural killer cells.
S Harsha, Krovi, Laurent, Gapin
openaire +2 more sources
Ligation of iNKT TCRs as a novel approach to activate iNKT cells for cancer immunotherapy
The Journal of Immunology, 2017Abstract Invariant natural killer T (iNKT) cells are innate-like T cells with an invariant TCRa chain and are restricted by CD1d. The activation of iNKT cells has demonstrated potent anti-tumor activity. Current anti-tumor clinical trials using the iNKT cell ligand, a-galactosylceramide (a-GalCer) have had limited success.
Weiming Yuan +2 more
openaire +1 more source
iNKT cells for allogeneic cell therapy
Cell and Gene Therapy Insights, 2023Eleni Chantzoura, Paul Ibbett
openaire +1 more source
iNKT cell agonists as vaccine adjuvants to combat infectious diseases
Carbohydrate Research, 2022Rui Luo
exaly
iNKT cell autoreactivity: what is 'self' and how is it recognized?
Nature Reviews Immunology, 2010Laurent Gapin, Gapin Laurent
exaly

